skin cancer research

World-wide skin cancer epidemiologyThe incidence of melanoma appears to be on the rise except for that observed in the younger population, underscoring a positive trend and hope for the fight against skin cancer.
Promising SK drug’s trials enter final phasesResults from a phase 2b clinical trial suggest that the Aclaris Therapeutics drug A-101 performed well . Find out how.
“Glutamine Addiction” Fuels MelanomaMelanoma cells proliferate and thrive with access to glutamine. Learn what one study found happens without the protein building amino acid.
Experimental small molecule inhibitor shows promise as melanoma treatment optionTAK-33 inhibited and regressed tumor growth in melanoma cell lines and patient-derived xenograft models. This “robust” success in the lab, according to a study published in Nov. 5, 2014 in Molecular Cancer Therapeutics, justifies continued clinical development as a potential therapy for melanoma patients.
Latest updates on advanced BCC treatment researchAdvanced basal cell carcinoma (aBCC) is a term used to describe a subset of basal cell carcinomas (BCCs) that have extensive, invasive or metastatic involvement; are located near vital and sensitive areas; or are recurrent despite multiple treatments. The diagnosis of aBCC is dependent on many patient specific factors, some of which are subjective and may be open to interpretation by both the patient and provider.
Biomarker could help guide melanoma treatmentResearchers have identified a functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting the gene. The finding could help guide treatment of patients with these cancers.